Kardiologia Polska,
Journal Year:
2024,
Volume and Issue:
82(5), P. 485 - 491
Published: May 8, 2024
Statin
therapy
is
a
cornerstone
in
the
management
of
dyslipidemia,
both
primary
and
secondary
prevention
cardiovascular
events.
Despite
strong
guidelines
supporting
statin
use,
concerns
regarding
side
effects,
particularly
musculoskeletal
symptoms,
contribute
to
intolerance
patient
reluctance.
While
reported
5%
30%
patients,
its
true
prevalence
may
be
overestimated
due
influence
nocebo
effect.
Factors
associated
with
higher
incidence
include
older
age,
female
sex,
comorbidities
such
as
diabetes
chronic
kidney
disease,
concurrent
use
medications
antiarrhythmic
agents
or
calcium
channel
blockers.
Clinical
characterization
requires
thorough
evaluation
exclusion
alternative
causes
symptoms.
Strategies
address
reassessing
risk,
engaging
shared
decision-making,
rechallenge
after
appropriate
washout
periods,
dosage
titration
for
tolerability,
consideration
therapies
when
low-density
lipoprotein
goals
cannot
achieved
statins.
This
review
provides
an
overview
spectrum
intolerance,
clinical
assessment,
systematic
approach
caring
intolerance.
Circulation,
Journal Year:
2023,
Volume and Issue:
148(9)
Published: July 20, 2023
AIM:
The
“2023
AHA/ACC/ACCP/ASPC/NLA/PCNA
Guideline
for
the
Management
of
Patients
With
Chronic
Coronary
Disease”
provides
an
update
to
and
consolidates
new
evidence
since
“2012
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS
Diagnosis
Stable
Ischemic
Heart
corresponding
“2014
ACC/AHA/AATS/PCNA/SCAI/STS
Focused
Update
Disease.”
METHODS:
A
comprehensive
literature
search
was
conducted
from
September
2021
May
2022.
Clinical
studies,
systematic
reviews
meta-analyses,
other
on
human
participants
were
identified
that
published
in
English
MEDLINE
(through
PubMed),
EMBASE,
Cochrane
Library,
Agency
Healthcare
Research
Quality,
selected
databases
relevant
this
guideline.
STRUCTURE:
This
guideline
evidenced-based
patient-centered
approach
management
patients
with
chronic
coronary
disease,
considering
social
determinants
health
incorporating
principles
shared
decision-making
team-based
care.
Relevant
topics
include
general
approaches
treatment
decisions,
guideline-directed
therapy
reduce
symptoms
future
cardiovascular
events,
pertaining
revascularization
recommendations
special
populations,
patient
follow-up
monitoring,
gaps,
areas
need
research.
Where
applicable,
based
availability
cost-effectiveness
data,
cost–value
are
also
provided
clinicians.
Many
previously
guidelines
have
been
updated
evidence,
created
when
supported
by
data.
Diabetes Care,
Journal Year:
2023,
Volume and Issue:
47(Supplement_1), P. S179 - S218
Published: Dec. 11, 2023
The
American
Diabetes
Association
(ADA)
"Standards
of
Care
in
Diabetes"
includes
the
ADA's
current
clinical
practice
recommendations
and
is
intended
to
provide
components
diabetes
care,
general
treatment
goals
guidelines,
tools
evaluate
quality
care.
Members
ADA
Professional
Practice
Committee,
an
interprofessional
expert
committee,
are
responsible
for
updating
Standards
annually,
or
more
frequently
as
warranted.
For
a
detailed
description
standards,
statements,
reports,
well
evidence-grading
system
full
list
Committee
members,
please
refer
Introduction
Methodology.
Readers
who
wish
comment
on
invited
do
so
at
professional.diabetes.org/SOC.
Journal of the American College of Cardiology,
Journal Year:
2024,
Volume and Issue:
83(20), P. 1939 - 1952
Published: April 7, 2024
Most
patients
with
atherosclerotic
cardiovascular
disease
(ASCVD)
fail
to
achieve
guideline-directed
low-density
lipoprotein
cholesterol
(LDL-C)
goals.
Twice-yearly
inclisiran
lowers
LDL-C
by
∼50%
when
added
statins.
To
evaluate
the
effectiveness
of
an
"inclisiran
first"
implementation
strategy
(adding
immediately
upon
failure
reach
<70
mg/dL
despite
receiving
maximally
tolerated
statins)
versus
representative
usual
care
in
US
ASCVD.
VICTORION-INITIATE,
a
prospective,
pragmatically
designed
trial,
randomized
1:1
(284
mg
at
Days
0,
90,
and
270)
plus
(lipid
management
treating
physician's
discretion)
alone.
Primary
endpoints
were
percentage
change
from
baseline
statin
discontinuation
rates.
We
450
(30.9%
female,
12.4%
Black,
15.3%
Hispanic);
mean
97.4
mg/dL.
The
led
significantly
greater
reductions
Day
330
(60.0%
vs
7.0%;
p<0.001).
Statin
rates
(6.0%)
noninferior
(16.7%).
More
achieved
goals
(<70
mg/dL:
81.8%
22.2%;
<55
71.6%
8.9%;
Treatment-emergent
adverse
event
(TEAE)
serious
TEAE
compared
similarly
between
treatment
strategies
(62.8%
53.7%
11.5%
13.4%,
respectively).
Injection-site
TEAEs
causing
withdrawal
occurred
more
commonly
than
(10.3%
0.0%,
2.6%
0.5%,
An
lowering
without
discouraging
use
or
raising
new
safety
concerns.
Diabetes Care,
Journal Year:
2024,
Volume and Issue:
48(Supplement_1), P. S207 - S238
Published: Dec. 9, 2024
The
American
Diabetes
Association
(ADA)
"Standards
of
Care
in
Diabetes"
includes
the
ADA's
current
clinical
practice
recommendations
and
is
intended
to
provide
components
diabetes
care,
general
treatment
goals
guidelines,
tools
evaluate
quality
care.
Members
ADA
Professional
Practice
Committee,
an
interprofessional
expert
committee,
are
responsible
for
updating
Standards
annually,
or
more
frequently
as
warranted.
For
a
detailed
description
standards,
statements,
reports,
well
evidence-grading
system
full
list
Committee
members,
please
refer
Introduction
Methodology.
Readers
who
wish
comment
on
invited
do
so
at
professional.diabetes.org/SOC.
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(2), P. 214 - 214
Published: Feb. 1, 2024
HMG-CoA
reductase
inhibitors,
commonly
known
as
statins,
are
the
primary
treatment
choice
for
cardiovascular
diseases,
which
stand
leading
global
cause
of
mortality.
Statins
also
offer
various
pleiotropic
effects,
including
improved
endothelial
function,
anti-inflammatory
properties,
reduced
oxidative
stress,
anti-thrombotic
and
stabilization
atherosclerotic
plaques.
However,
usage
statins
can
be
accompanied
by
a
range
adverse
such
development
type
2
diabetes
mellitus,
muscular
symptoms,
liver
toxicity,
kidney
cataracts,
hemorrhagic
strokes,
psychiatric
complications.
These
issues
referred
to
statin-associated
symptoms
(SAS)
relatively
infrequent
in
clinical
trials,
making
it
challenging
attribute
them
statin
use
definitively.
Therefore,
these
lead
significant
problems,
necessitating
dose
adjustments
or
discontinuation
therapy.
This
review
aims
provide
comprehensive
overview
mechanism
action,
potential
advantages,
associated
risks
utilization
settings.
Circulation,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 27, 2025
Aim:
The
“2025
ACC/AHA/ACEP/NAEMSP/SCAI
Guideline
for
the
Management
of
Patients
With
Acute
Coronary
Syndromes”
incorporates
new
evidence
since
“2013
ACCF/AHA
ST-Elevation
Myocardial
Infarction”
and
corresponding
“2014
AHA/ACC
Non–ST-Elevation
“2015
ACC/AHA/SCAI
Focused
Update
on
Primary
Percutaneous
Intervention
Infarction.”
“2021
Artery
Revascularization”
retire
replace,
respectively,
“2016
ACC/AHA
Duration
Dual
Antiplatelet
Therapy
in
Disease.”
Methods:
A
comprehensive
literature
search
was
conducted
from
July
2023
to
April
2024.
Clinical
studies,
systematic
reviews
meta-analyses,
other
human
participants
were
identified
that
published
English
MEDLINE
(through
PubMed),
EMBASE,
Cochrane
Library,
Agency
Healthcare
Research
Quality,
selected
databases
relevant
this
guideline.
Structure:
Many
recommendations
previously
guidelines
have
been
updated
with
evidence,
created
when
supported
by
data.
Journal of clinical lipidology,
Journal Year:
2022,
Volume and Issue:
17(1), P. 19 - 39
Published: Sept. 11, 2022
Statin-associated
muscle
symptoms
(SAMS)
are
the
most
common
form
of
statin
intolerance
and
associated
with
increased
risk
cardiovascular
events
that
manifest
from
underutilization
discontinuation.
The
reported
frequencies
SAMS
divergent
in
literature.
writing
group
estimates
prevalence
SAMS,
namely
all
temporally
related
to
use
but
without
regard
causality,
be
about
10%
(range
5%
25%),
pharmacological
specifically
resulting
properties
statin,
1-2%
0.5%
4%).
In
clinical
practice,
likely
result
a
combination
nonpharmacological
effects,
however
this
does
not
make
any
less
clinically
relevant.
Regardless
etiology,
need
addressed
accordance
patients'
preferences
experiences.
This
perspective
reviews
epidemiology
underlying
pathophysiology
consequences
We
present
patient-centered
communication
strategies
mitigate
improve
medication
adherence
outcomes
among
users.
Treatment
include
1)
optimizing
lifestyle
interventions,
2)
modulating
factors
may
contribute
symptoms,
3)
tolerability
by
dose
reduction,
decreased
dosing
frequency,
or
an
alternate
more
favorable
pharmacokinetic
properties,
4)
non-statins,
emphasizing
those
evidence
for
atherosclerotic
either
place
therapy
depending
on
patient's
circumstances.
focus
is
sustainable
lipoprotein
goal
achievement,
which
important
reduction.
